首页 > 最新文献

Current Hypertension Reports最新文献

英文 中文
Considering Adverse Effects of Common Antihypertensive Medications in the ED 考虑急诊室常用抗高血压药物的不良反应
IF 5.6 2区 医学 Q1 Medicine Pub Date : 2024-04-30 DOI: 10.1007/s11906-024-01304-5
Charles R. Wira, Thomas Kearns, Alex Fleming-Nouri, John D. Tyrrell, Christina M. Wira, Ani Aydin

Purpose of Review

To evaluate the adverse effects of common antihypertensive agents utilized or encountered in the Emergency Department.

Recent Findings

All categories of antihypertensive agents may manifest adverse effects, inclusive of adverse drug reactions (ADRs), drug-to-drug interactions, or accidental overdose. Adverse effects, and specifically ADRs, may be stratified into the organ systems affected, might require specific time-sensitive interventions, could pose particular risks to vulnerable populations, and may result in significant morbidity, and potential mortality.

Summary

Adverse effects of common antihypertensive agents may be encountered in the ED, necessitating that ED systems of care are poised to prevent, recognize, and intervene when adverse effects arise.

最新研究结果所有类别的降压药都可能出现不良反应,包括药物不良反应 (ADR)、药物间相互作用或意外过量。不良反应,尤其是药物不良反应,可能会根据受影响的器官系统进行分层,可能需要特定的时间敏感性干预措施,可能会对易感人群造成特殊风险,并可能导致严重的发病率和潜在的死亡率。摘要常见降压药的不良反应可能会在急诊室出现,因此急诊室的护理系统必须做好准备,以便在出现不良反应时进行预防、识别和干预。
{"title":"Considering Adverse Effects of Common Antihypertensive Medications in the ED","authors":"Charles R. Wira, Thomas Kearns, Alex Fleming-Nouri, John D. Tyrrell, Christina M. Wira, Ani Aydin","doi":"10.1007/s11906-024-01304-5","DOIUrl":"https://doi.org/10.1007/s11906-024-01304-5","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3><p>To evaluate the adverse effects of common antihypertensive agents utilized or encountered in the Emergency Department.</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>All categories of antihypertensive agents may manifest adverse effects, inclusive of adverse drug reactions (ADRs), drug-to-drug interactions, or accidental overdose. Adverse effects, and specifically ADRs, may be stratified into the organ systems affected, might require specific time-sensitive interventions, could pose particular risks to vulnerable populations, and may result in significant morbidity, and potential mortality.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>Adverse effects of common antihypertensive agents may be encountered in the ED, necessitating that ED systems of care are poised to prevent, recognize, and intervene when adverse effects arise.</p>","PeriodicalId":10963,"journal":{"name":"Current Hypertension Reports","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140834084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Breaking the Barrier: The Role of Gut Epithelial Permeability in the Pathogenesis of Hypertension. 打破屏障:肠道上皮渗透性在高血压发病机制中的作用。
IF 5.6 2区 医学 Q1 Medicine Pub Date : 2024-04-25 DOI: 10.1007/s11906-024-01307-2
M. Snelson, T. Vanuytsel, Francine Z Marques
{"title":"Breaking the Barrier: The Role of Gut Epithelial Permeability in the Pathogenesis of Hypertension.","authors":"M. Snelson, T. Vanuytsel, Francine Z Marques","doi":"10.1007/s11906-024-01307-2","DOIUrl":"https://doi.org/10.1007/s11906-024-01307-2","url":null,"abstract":"","PeriodicalId":10963,"journal":{"name":"Current Hypertension Reports","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140655671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epicardial Adipose Tissue Thickness and Preserved Ejection Fraction Heart Failure 心外膜脂肪组织厚度与保留射血分数心衰
IF 5.6 2区 医学 Q1 Medicine Pub Date : 2024-04-20 DOI: 10.1007/s11906-024-01302-7
Aneesh Dhore-Patil, Daniela Urina-Jassir, Rohan Samson, Thierry H. Le Jemtel, Suzanne Oparil

Purpose of the Review

Preserved ejection fraction heart failure and obesity frequently coexist. Whether obesity plays a consistent role in the pathogenesis of preserved ejection fraction heart failure is unclear. Accumulation of visceral adiposity underlies the pathogenic aftermaths of obesity. However, visceral adiposity imaging is assessed by computed tomography or magnetic resonance and thus not routinely available. In contrast, epicardial adiposity thickness is assessed by echocardiography and thus routinely available. We review the rationale for assessing epicardial adiposity thickness in patients with preserved ejection fraction heart failure and elevated body mass index.

Recent Findings

Body mass index correlates poorly with visceral, and epicardial adiposity. Visceral and epicardial adiposity enlarges as preserved ejection fraction heart failure progresses. Epicardial adiposity may hasten the progression of coronary artery disease and impairs left ventricular sub-endocardial perfusion and diastolic function.

Summary

Epicardial adiposity thickness may help monitor the therapeutic response in patients with preserved ejection failure heart failure and elevated body mass index.

综述目的射血分数保留型心力衰竭和肥胖经常同时存在。肥胖在射血分数保留型心力衰竭的发病机制中是否起着一致的作用尚不清楚。内脏脂肪堆积是肥胖致病后遗症的基础。然而,内脏脂肪成像是通过计算机断层扫描或磁共振成像进行评估的,因此并不常见。与此相反,心外膜脂肪厚度可通过超声心动图进行评估,因此可常规使用。我们回顾了在射血分数保留、体重指数升高的心力衰竭患者中评估心外膜脂肪厚度的基本原理。内脏和心外膜脂肪随着射血分数保留型心力衰竭的进展而增加。摘要心外膜脂肪厚度有助于监测射血分数保留型心力衰竭患者的治疗反应。
{"title":"Epicardial Adipose Tissue Thickness and Preserved Ejection Fraction Heart Failure","authors":"Aneesh Dhore-Patil, Daniela Urina-Jassir, Rohan Samson, Thierry H. Le Jemtel, Suzanne Oparil","doi":"10.1007/s11906-024-01302-7","DOIUrl":"https://doi.org/10.1007/s11906-024-01302-7","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of the Review</h3><p>Preserved ejection fraction heart failure and obesity frequently coexist. Whether obesity plays a consistent role in the pathogenesis of preserved ejection fraction heart failure is unclear. Accumulation of visceral adiposity underlies the pathogenic aftermaths of obesity. However, visceral adiposity imaging is assessed by computed tomography or magnetic resonance and thus not routinely available. In contrast, epicardial adiposity thickness is assessed by echocardiography and thus routinely available. We review the rationale for assessing epicardial adiposity thickness in patients with preserved ejection fraction heart failure and elevated body mass index.</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>Body mass index correlates poorly with visceral, and epicardial adiposity. Visceral and epicardial adiposity enlarges as preserved ejection fraction heart failure progresses. Epicardial adiposity may hasten the progression of coronary artery disease and impairs left ventricular sub-endocardial perfusion and diastolic function.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>Epicardial adiposity thickness may help monitor the therapeutic response in patients with preserved ejection failure heart failure and elevated body mass index.</p>","PeriodicalId":10963,"journal":{"name":"Current Hypertension Reports","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140628025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neuroimmunology of Cardiovascular Disease 心血管疾病的神经免疫学
IF 5.6 2区 医学 Q1 Medicine Pub Date : 2024-04-13 DOI: 10.1007/s11906-024-01301-8
Sara M. Zarate, Annet Kirabo, Antentor O. Hinton Jr., Monica M. Santisteban

Purpose of Review

Cardiovascular disease (CVD) is a leading cause of death and chronic disability worldwide. Yet, despite extensive intervention strategies the number of persons affected by CVD continues to rise. Thus, there is great interest in unveiling novel mechanisms that may lead to new treatments. Considering this dilemma, recent focus has turned to the neuroimmune mechanisms involved in CVD pathology leading to a deeper understanding of the brain’s involvement in disease pathology. This review provides an overview of new and salient findings regarding the neuroimmune mechanisms that contribute to CVD.

Recent Findings

The brain contains neuroimmune niches comprised of glia in the parenchyma and immune cells at the brain’s borders, and there is strong evidence that these neuroimmune niches are important in both health and disease. Mechanistic studies suggest that the activation of glia and immune cells in these niches modulates CVD progression in hypertension and heart failure and contributes to the inevitable end-organ damage to the brain.

Summary

This review provides evidence supporting the role of neuroimmune niches in CVD progression. However, additional research is needed to understand the effects of prolonged neuroimmune activation on brain function.

综述目的心血管疾病(CVD)是导致全球死亡和慢性残疾的主要原因。然而,尽管采取了广泛的干预策略,受心血管疾病影响的人数仍在继续增加。因此,人们对揭示可能导致新疗法的新机制非常感兴趣。考虑到这一困境,最近的研究重点转向了心血管疾病病理中的神经免疫机制,从而加深了对大脑参与疾病病理的理解。本综述概述了有关导致心血管疾病的神经免疫机制的新的和突出的发现。最近的发现大脑包含神经免疫龛,由实质中的神经胶质细胞和大脑边界的免疫细胞组成,有强有力的证据表明这些神经免疫龛在健康和疾病中都很重要。机理研究表明,这些龛位中神经胶质细胞和免疫细胞的活化调节了高血压和心力衰竭的心血管疾病进展,并导致了不可避免的大脑终末器官损伤。然而,要了解神经免疫长期激活对大脑功能的影响,还需要进行更多的研究。
{"title":"Neuroimmunology of Cardiovascular Disease","authors":"Sara M. Zarate, Annet Kirabo, Antentor O. Hinton Jr., Monica M. Santisteban","doi":"10.1007/s11906-024-01301-8","DOIUrl":"https://doi.org/10.1007/s11906-024-01301-8","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3><p>Cardiovascular disease (CVD) is a leading cause of death and chronic disability worldwide. Yet, despite extensive intervention strategies the number of persons affected by CVD continues to rise. Thus, there is great interest in unveiling novel mechanisms that may lead to new treatments. Considering this dilemma, recent focus has turned to the neuroimmune mechanisms involved in CVD pathology leading to a deeper understanding of the brain’s involvement in disease pathology. This review provides an overview of new and salient findings regarding the neuroimmune mechanisms that contribute to CVD.</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>The brain contains neuroimmune niches comprised of glia in the parenchyma and immune cells at the brain’s borders, and there is strong evidence that these neuroimmune niches are important in both health and disease. Mechanistic studies suggest that the activation of glia and immune cells in these niches modulates CVD progression in hypertension and heart failure and contributes to the inevitable end-organ damage to the brain.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>This review provides evidence supporting the role of neuroimmune niches in CVD progression. However, additional research is needed to understand the effects of prolonged neuroimmune activation on brain function.</p>","PeriodicalId":10963,"journal":{"name":"Current Hypertension Reports","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140562453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endoplasmic Reticulum Stress in Hypertension and Salt Sensitivity of Blood Pressure 高血压中的内质网应激和血压对盐的敏感性
IF 5.6 2区 医学 Q1 Medicine Pub Date : 2024-04-11 DOI: 10.1007/s11906-024-01300-9
Maria Balhara, Kit Neikirk, Andrea Marshall, Antentor Hinton, Annet Kirabo

Purpose of Review

Hypertension is a principal risk factor for cardiovascular morbidity and mortality, with its severity exacerbated by high sodium intake, particularly in individuals with salt-sensitive blood pressure. However, the mechanisms underlying hypertension and salt sensitivity are only partly understood. Herein, we review potential interactions in hypertension pathophysiology involving the immune system, endoplasmic reticulum (ER) stress, the unfolded protein response (UPR), and proteostasis pathways; identify knowledge gaps; and discuss future directions.

Recent Findings

Recent advancements by our research group and others reveal interactions within and between adaptive and innate immune responses in hypertension pathophysiology. The salt-immune-hypertension axis is further supported by the discovery of the role of dendritic cells in hypertension, marked by isolevuglandin (IsoLG) formation. Alongside these broadened understandings of immune-mediated salt sensitivity, the contributions of T cells to hypertension have been recently challenged by groups whose findings did not support increased resistance of Rag-1-deficient mice to Ang II infusion. Hypertension has also been linked to ER stress and the UPR. Notably, a holistic approach is needed because the UPR engages in crosstalk with autophagy, the ubiquitin proteasome, and other proteostasis pathways, that may all involve hypertension.

Summary

There is a critical need for studies to establish cause and effect relationships between ER stress and the UPR in hypertension pathophysiology in humans and to determine whether the immune system and ER stress function mainly to exacerbate or initiate hypertension and target organ injury. This review of recent studies proposes new avenues for future research for targeted therapeutic interventions.

综述目的高血压是心血管疾病发病率和死亡率的主要风险因素,高钠摄入会加剧高血压的严重程度,对盐敏感的血压患者尤其如此。然而,人们对高血压和盐敏感性的内在机制仅有部分了解。在此,我们回顾了高血压病理生理学中涉及免疫系统、内质网(ER)应激、未折叠蛋白反应(UPR)和蛋白稳态途径的潜在相互作用,找出了知识差距,并讨论了未来的研究方向。最近的研究结果我们研究小组和其他研究小组的最新研究进展揭示了高血压病理生理学中适应性免疫反应和先天性免疫反应内部和之间的相互作用。树突状细胞在高血压中的作用(以异钩藤素(IsoLG)的形成为标志)的发现进一步支持了盐-免疫-高血压轴。在拓宽对免疫介导的盐敏感性的认识的同时,T 细胞对高血压的作用最近也受到了一些研究小组的质疑,他们的研究结果并不支持 Rag-1 缺陷小鼠对 Ang II 输注的抵抗力增强。高血压还与 ER 应激和 UPR 有关。值得注意的是,由于 UPR 与自噬、泛素蛋白酶体和其他蛋白稳态途径相互交织,可能都与高血压有关,因此需要采取综合的方法。摘要目前亟需开展研究,以确定 ER 应激和 UPR 在人类高血压病理生理学中的因果关系,并确定免疫系统和 ER 应激的功能是否主要加剧或引发高血压和靶器官损伤。这篇最新研究综述提出了未来研究的新途径,以便进行有针对性的治疗干预。
{"title":"Endoplasmic Reticulum Stress in Hypertension and Salt Sensitivity of Blood Pressure","authors":"Maria Balhara, Kit Neikirk, Andrea Marshall, Antentor Hinton, Annet Kirabo","doi":"10.1007/s11906-024-01300-9","DOIUrl":"https://doi.org/10.1007/s11906-024-01300-9","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3><p>Hypertension is a principal risk factor for cardiovascular morbidity and mortality, with its severity exacerbated by high sodium intake, particularly in individuals with salt-sensitive blood pressure. However, the mechanisms underlying hypertension and salt sensitivity are only partly understood. Herein, we review potential interactions in hypertension pathophysiology involving the immune system, endoplasmic reticulum (ER) stress, the unfolded protein response (UPR), and proteostasis pathways; identify knowledge gaps; and discuss future directions.</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>Recent advancements by our research group and others reveal interactions within and between adaptive and innate immune responses in hypertension pathophysiology. The salt-immune-hypertension axis is further supported by the discovery of the role of dendritic cells in hypertension, marked by isolevuglandin (IsoLG) formation. Alongside these broadened understandings of immune-mediated salt sensitivity, the contributions of T cells to hypertension have been recently challenged by groups whose findings did not support increased resistance of Rag-1-deficient mice to Ang II infusion. Hypertension has also been linked to ER stress and the UPR. Notably, a holistic approach is needed because the UPR engages in crosstalk with autophagy, the ubiquitin proteasome, and other proteostasis pathways, that may all involve hypertension.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>There is a critical need for studies to establish cause and effect relationships between ER stress and the UPR in hypertension pathophysiology in humans and to determine whether the immune system and ER stress function mainly to exacerbate or initiate hypertension and target organ injury. This review of recent studies proposes new avenues for future research for targeted therapeutic interventions.</p>","PeriodicalId":10963,"journal":{"name":"Current Hypertension Reports","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140562637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HEARTS in the Americas: Targeting Health System Change to Improve Population Hypertension Control. 美洲的心脏:以卫生系统变革为目标,改善人群高血压控制。
IF 5.6 2区 医学 Q1 Medicine Pub Date : 2024-04-01 Epub Date: 2023-12-02 DOI: 10.1007/s11906-023-01286-w
Pedro Ordunez, Norm R C Campbell, Donald J DiPette, Marc G Jaffe, Andres Rosende, Ramon Martinez, Angelo Gamarra, Cintia Lombardi, Natalia Parra, Libardo Rodriguez, Yenny Rodriguez, Jeffrey Brettler

Purpose of review: HEARTS in the Americas is the regional adaptation of Global Hearts, the World Health Organization initiative for cardiovascular disease (CVD) prevention and control. Its overarching goal is to drive health services to change managerial and clinical practice in primary care settings to improve hypertension control and CVD risk management. This review describes the HEARTS in the Americas initiative. First, the regional epidemiological situation of CVD mortality and population hypertension control trends are summarized; then the rationale for its main intervention components: the primary care-oriented management system and the HEARTS Clinical Pathway are described. Finally, the key factors for accelerating the expansion of HEARTS are examined: medicines, team-based care, and a system for monitoring and evaluation.

Recent findings: Thus far, 33 countries in Latin America and the Caribbean have committed to integrating this program across their primary healthcare network by 2025. The increase in hypertension coverage and control in primary health care settings compared with the traditional model is promising and confirms that the interventions under the HEARTS umbrella are feasible and acceptable to communities, patients, providers, decision-makers, and funders. This review highlights some cases of successful implementation. Scaling up effective treatment for hypertension and optimization of CVD risk management is a pragmatic way to accelerate the reduction of CVD mortality while strengthening primary healthcare systems to respond effectively, with quality, and equitably, to the challenge of non-communicable diseases, not only in low-middle income countries but in all communities globally.

审查目的:美洲的HEARTS是世界卫生组织心血管疾病(CVD)预防和控制倡议“全球心脏”的区域调整。其总体目标是推动卫生服务改变初级保健机构的管理和临床实践,以改善高血压控制和心血管疾病风险管理。本综述描述了美洲的HEARTS倡议。首先,总结了各地区心血管疾病死亡率和人群高血压控制趋势的流行病学情况;然后描述了其主要干预成分的基本原理:初级保健导向管理系统和HEARTS临床路径。最后,对加速扩大HEARTS的关键因素进行了审查:药物、以团队为基础的护理以及监测和评估系统。最近的发现:迄今为止,拉丁美洲和加勒比地区已有33个国家承诺到2025年将这一规划纳入其初级卫生保健网络。与传统模式相比,初级卫生保健机构高血压覆盖率和控制的增加是有希望的,并证实了HEARTS保护伞下的干预措施对社区、患者、提供者、决策者和资助者来说是可行和可接受的。这次审查突出了一些成功实施的案例。扩大对高血压的有效治疗和优化心血管疾病风险管理是一种务实的方式,可以加速降低心血管疾病死亡率,同时加强初级卫生保健系统,以有效、高质量和公平地应对非传染性疾病的挑战,不仅在中低收入国家,而且在全球所有社区。
{"title":"HEARTS in the Americas: Targeting Health System Change to Improve Population Hypertension Control.","authors":"Pedro Ordunez, Norm R C Campbell, Donald J DiPette, Marc G Jaffe, Andres Rosende, Ramon Martinez, Angelo Gamarra, Cintia Lombardi, Natalia Parra, Libardo Rodriguez, Yenny Rodriguez, Jeffrey Brettler","doi":"10.1007/s11906-023-01286-w","DOIUrl":"10.1007/s11906-023-01286-w","url":null,"abstract":"<p><strong>Purpose of review: </strong>HEARTS in the Americas is the regional adaptation of Global Hearts, the World Health Organization initiative for cardiovascular disease (CVD) prevention and control. Its overarching goal is to drive health services to change managerial and clinical practice in primary care settings to improve hypertension control and CVD risk management. This review describes the HEARTS in the Americas initiative. First, the regional epidemiological situation of CVD mortality and population hypertension control trends are summarized; then the rationale for its main intervention components: the primary care-oriented management system and the HEARTS Clinical Pathway are described. Finally, the key factors for accelerating the expansion of HEARTS are examined: medicines, team-based care, and a system for monitoring and evaluation.</p><p><strong>Recent findings: </strong>Thus far, 33 countries in Latin America and the Caribbean have committed to integrating this program across their primary healthcare network by 2025. The increase in hypertension coverage and control in primary health care settings compared with the traditional model is promising and confirms that the interventions under the HEARTS umbrella are feasible and acceptable to communities, patients, providers, decision-makers, and funders. This review highlights some cases of successful implementation. Scaling up effective treatment for hypertension and optimization of CVD risk management is a pragmatic way to accelerate the reduction of CVD mortality while strengthening primary healthcare systems to respond effectively, with quality, and equitably, to the challenge of non-communicable diseases, not only in low-middle income countries but in all communities globally.</p>","PeriodicalId":10963,"journal":{"name":"Current Hypertension Reports","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10904446/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138470081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cell-Free Nucleic Acids for Early Prediction of Preeclampsia. 用于子痫前期早期预测的无细胞核酸。
IF 5.6 2区 医学 Q1 Medicine Pub Date : 2024-04-01 Epub Date: 2023-12-26 DOI: 10.1007/s11906-023-01291-z
Mira N Moufarrej, Virginia D Winn, Stephen R Quake

Purpose of review: This review summarizes the potential of cell-free nucleic acids for predicting preeclampsia, contrasts them with other methods, and discusses these findings' relevance to preeclampsia's pathogenesis and care.

Recent findings: Recent studies have demonstrated the utility of cell-free nucleic acids in early preeclampsia risk prediction. Encouragingly, nucleic acid measurement exhibits similar or better sensitivity as compared to standard screening assays and furthermore sheds light on preeclampsia's underlying placental biology. Over the past decade, liquid biopsies measuring cell-free nucleic acids have found diverse applications, including in prenatal care. Recent advances have extended their utility to predict preeclampsia, a major cause of maternal mortality. These assays assess methylation patterns in cell-free DNA (cfDNA) or gene levels in cell-free RNA (cfRNA). Currently, preeclampsia care focuses on blood pressure control, seizure prevention, and delivery. If validated, early prediction of preeclampsia through liquid biopsies can improve maternal health and deepen our understanding of its causes.

综述的目的:本综述总结了无细胞核酸预测子痫前期的潜力,将其与其他方法进行了对比,并讨论了这些发现与子痫前期发病机制和护理的相关性:最近的研究表明,无细胞核酸可用于早期子痫前期的风险预测。令人鼓舞的是,与标准筛查测定相比,核酸测定显示出相似或更高的灵敏度,并进一步揭示了子痫前期潜在的胎盘生物学特性。在过去的十年中,测量无细胞核酸的液体活检技术得到了广泛的应用,包括在产前护理中。最近的进展将其用途扩展到预测子痫前期,这是孕产妇死亡的一个主要原因。这些检测方法可评估无细胞 DNA(cfDNA)中的甲基化模式或无细胞 RNA(cfRNA)中的基因水平。目前,子痫前期护理的重点是控制血压、预防癫痫发作和分娩。如果得到验证,通过液体活检对子痫前期进行早期预测可以改善产妇健康,加深我们对其病因的了解。
{"title":"Cell-Free Nucleic Acids for Early Prediction of Preeclampsia.","authors":"Mira N Moufarrej, Virginia D Winn, Stephen R Quake","doi":"10.1007/s11906-023-01291-z","DOIUrl":"10.1007/s11906-023-01291-z","url":null,"abstract":"<p><strong>Purpose of review: </strong>This review summarizes the potential of cell-free nucleic acids for predicting preeclampsia, contrasts them with other methods, and discusses these findings' relevance to preeclampsia's pathogenesis and care.</p><p><strong>Recent findings: </strong>Recent studies have demonstrated the utility of cell-free nucleic acids in early preeclampsia risk prediction. Encouragingly, nucleic acid measurement exhibits similar or better sensitivity as compared to standard screening assays and furthermore sheds light on preeclampsia's underlying placental biology. Over the past decade, liquid biopsies measuring cell-free nucleic acids have found diverse applications, including in prenatal care. Recent advances have extended their utility to predict preeclampsia, a major cause of maternal mortality. These assays assess methylation patterns in cell-free DNA (cfDNA) or gene levels in cell-free RNA (cfRNA). Currently, preeclampsia care focuses on blood pressure control, seizure prevention, and delivery. If validated, early prediction of preeclampsia through liquid biopsies can improve maternal health and deepen our understanding of its causes.</p>","PeriodicalId":10963,"journal":{"name":"Current Hypertension Reports","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139037515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Managing Hypertension in Older Adults. 管理老年人的高血压。
IF 5.6 2区 医学 Q1 Medicine Pub Date : 2024-04-01 Epub Date: 2023-12-27 DOI: 10.1007/s11906-023-01289-7
Brent M Egan, Holly J Mattix-Kramer, Jan N Basile, Susan E Sutherland

Purpose of review: The population of older adults 60-79 years globally is projected to double from 800 million to 1.6 billion between 2015 and 2050, while adults ≥ 80 years were forecast to more than triple from 125 to 430 million. The risk for cardiovascular events doubles with each decade of aging and each 20 mmHg increase of systolic blood pressure. Thus, successful management of hypertension in older adults is critical in mitigating the projected global health and economic burden of cardiovascular disease.

Recent findings: Women live longer than men, yet with aging systolic blood pressure and prevalent hypertension increase more, and hypertension control decreases more than in men, i.e., hypertension in older adults is disproportionately a women's health issue. Among older adults who are healthy to mildly frail, the absolute benefit of hypertension control, including more intensive control, on cardiovascular events is greater in adults ≥ 80 than 60-79 years old. The absolute rate of serious adverse events during antihypertensive therapy is greater in adults ≥ 80 years older than 60-79 years, yet the excess adverse event rate with intensive versus standard care is only moderately increased. Among adults ≥ 80 years, benefits of more intensive therapy appear non-existent to reversed with moderate to marked frailty and when cognitive function is less than roughly the twenty-fifth percentile. Accordingly, assessment of functional and cognitive status is important in setting blood pressure targets in older adults. Given substantial absolute cardiovascular benefits of more intensive antihypertensive therapy in independent-living older adults, this group merits shared-decision making for hypertension targets.

审查目的:预计在 2015 年至 2050 年期间,全球 60-79 岁的老年人口将翻一番,从 8 亿人增至 16 亿人,而≥80 岁的成年人预计将增加两倍多,从 1.25 亿人增至 4.3 亿人。年龄每增加 10 岁,收缩压每增加 20 mmHg,发生心血管事件的风险就会增加一倍。因此,成功控制老年人的高血压对减轻心血管疾病预计带来的全球健康和经济负担至关重要:最近的研究结果:女性的寿命比男性长,但随着年龄的增长,收缩压和高血压的发病率比男性增加得更多,高血压的控制率比男性下降得更多,也就是说,老年人的高血压是一个不成比例的女性健康问题。在健康到轻度虚弱的老年人中,控制高血压(包括加强控制)对心血管事件的绝对益处,≥ 80 岁的成年人要大于 60-79 岁的成年人。与 60-79 岁的成年人相比,≥ 80 岁的成年人在降压治疗期间发生严重不良事件的绝对比率更高,但强化治疗与标准治疗相比,不良事件的超额发生率仅略有增加。在年龄≥80 岁的成年人中,如果存在中度至明显的虚弱,且认知功能低于大约第 25 百分位数,那么强化治疗的益处似乎并不存在。因此,评估老年人的功能和认知状况对于设定血压目标非常重要。鉴于加强降压治疗对独立生活的老年人的心血管绝对大有裨益,这一群体值得共同决定高血压目标。
{"title":"Managing Hypertension in Older Adults.","authors":"Brent M Egan, Holly J Mattix-Kramer, Jan N Basile, Susan E Sutherland","doi":"10.1007/s11906-023-01289-7","DOIUrl":"10.1007/s11906-023-01289-7","url":null,"abstract":"<p><strong>Purpose of review: </strong>The population of older adults 60-79 years globally is projected to double from 800 million to 1.6 billion between 2015 and 2050, while adults ≥ 80 years were forecast to more than triple from 125 to 430 million. The risk for cardiovascular events doubles with each decade of aging and each 20 mmHg increase of systolic blood pressure. Thus, successful management of hypertension in older adults is critical in mitigating the projected global health and economic burden of cardiovascular disease.</p><p><strong>Recent findings: </strong>Women live longer than men, yet with aging systolic blood pressure and prevalent hypertension increase more, and hypertension control decreases more than in men, i.e., hypertension in older adults is disproportionately a women's health issue. Among older adults who are healthy to mildly frail, the absolute benefit of hypertension control, including more intensive control, on cardiovascular events is greater in adults ≥ 80 than 60-79 years old. The absolute rate of serious adverse events during antihypertensive therapy is greater in adults ≥ 80 years older than 60-79 years, yet the excess adverse event rate with intensive versus standard care is only moderately increased. Among adults ≥ 80 years, benefits of more intensive therapy appear non-existent to reversed with moderate to marked frailty and when cognitive function is less than roughly the twenty-fifth percentile. Accordingly, assessment of functional and cognitive status is important in setting blood pressure targets in older adults. Given substantial absolute cardiovascular benefits of more intensive antihypertensive therapy in independent-living older adults, this group merits shared-decision making for hypertension targets.</p>","PeriodicalId":10963,"journal":{"name":"Current Hypertension Reports","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10904451/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139039641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preeclampsia and the Retina. 子痫前期与视网膜。
IF 5.6 2区 医学 Q1 Medicine Pub Date : 2024-04-01 Epub Date: 2023-12-22 DOI: 10.1007/s11906-023-01290-0
Safiya Soullane, Marc-André Rhéaume, Nathalie Auger

Purpose of review: This review summarizes key findings relating to the association between preeclampsia and retinal disorders.

Recent findings: Preeclampsia is a major cause of maternal morbidity. Pregnant women with preeclampsia frequently describe having visual disturbances. Retinal changes can be identified on fundoscopy in most patients with preeclampsia. While retinal pathology secondary to preeclampsia usually resolves postpartum, there is growing evidence that women with preeclampsia have a higher long-term risk of developing retinal disorders after pregnancy. Pregnant women often experience visual changes. While these symptoms may be benign, careful attention should be paid to exclude retinal disorders secondary to preeclampsia. Pregnant women complaining of new-onset or worsening blurry vision, scotomata, diplopia, or photopsia require rapid and thorough evaluation to rule out hypertensive disorders. Management of preeclampsia, including administration of magnesium sulfate and delivery of the fetus, can reverse retinal pathologies in most cases.

综述的目的:本综述总结了与子痫前期和视网膜病变相关的主要研究结果:子痫前期是孕产妇发病的主要原因。患有子痫前期的孕妇经常会出现视力障碍。大多数先兆子痫患者都能通过眼底镜检查发现视网膜病变。虽然子痫前期继发的视网膜病变通常会在产后缓解,但越来越多的证据表明,患有子痫前期的妇女在妊娠后发生视网膜病变的长期风险较高。孕妇经常会出现视力变化。虽然这些症状可能是良性的,但应注意排除子痫前期继发的视网膜病变。如果孕妇主诉视力模糊、视物模糊、复视或光感等症状初发或加重,则需要进行快速、彻底的评估,以排除高血压疾病。子痫前期的治疗,包括服用硫酸镁和胎儿娩出,在大多数情况下可以逆转视网膜病变。
{"title":"Preeclampsia and the Retina.","authors":"Safiya Soullane, Marc-André Rhéaume, Nathalie Auger","doi":"10.1007/s11906-023-01290-0","DOIUrl":"10.1007/s11906-023-01290-0","url":null,"abstract":"<p><strong>Purpose of review: </strong>This review summarizes key findings relating to the association between preeclampsia and retinal disorders.</p><p><strong>Recent findings: </strong>Preeclampsia is a major cause of maternal morbidity. Pregnant women with preeclampsia frequently describe having visual disturbances. Retinal changes can be identified on fundoscopy in most patients with preeclampsia. While retinal pathology secondary to preeclampsia usually resolves postpartum, there is growing evidence that women with preeclampsia have a higher long-term risk of developing retinal disorders after pregnancy. Pregnant women often experience visual changes. While these symptoms may be benign, careful attention should be paid to exclude retinal disorders secondary to preeclampsia. Pregnant women complaining of new-onset or worsening blurry vision, scotomata, diplopia, or photopsia require rapid and thorough evaluation to rule out hypertensive disorders. Management of preeclampsia, including administration of magnesium sulfate and delivery of the fetus, can reverse retinal pathologies in most cases.</p>","PeriodicalId":10963,"journal":{"name":"Current Hypertension Reports","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138828671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Slow on the Draw-ED Management of Elevated BP in Older Adults. 老年人血压升高的抽ed治疗进展缓慢。
IF 5.6 2区 医学 Q1 Medicine Pub Date : 2024-03-01 Epub Date: 2023-11-21 DOI: 10.1007/s11906-023-01284-y
Kianna Eurick-Bering, Brett Todd, Lauren Cameron-Comasco

Purpose of review: The purpose of this study is to review data surrounding the emergency department management of elevated blood pressure in older adults, including the management of hypertensive crisis and outpatient management of markedly elevated blood pressure.

Recent findings: Acute lowering of blood pressure in older adults with markedly elevated blood pressure may lead to serious complications without improvements in hospital length of stay, return visits, or mortality. Older adults presenting with elevated blood pressures without evidence of end-organ damage should be referred for outpatient management of their blood pressure. Treatment of hypertensive emergency should follow standard guidelines with additional considerations for aging physiology. Acute lowering of elevated blood pressure in older adults without evidence of end-organ damage has the potential for harm. If the emergency physician opts to acutely treat, they should consider the increased risk of side effects in older adults and avoid Beers list medications including short-acting nifedipine and clonidine.

回顾目的:本研究的目的是回顾有关老年人高血压急诊科管理的数据,包括高血压危象的管理和门诊血压明显升高的管理。近期研究发现:在血压明显升高的老年人中,急性降压可能导致严重的并发症,而不会改善住院时间、复诊或死亡率。出现血压升高而无终末器官损伤证据的老年人应转诊接受门诊血压管理。高血压急诊的治疗应遵循标准指南,并考虑到衰老生理。在没有终末器官损伤证据的老年人中,急性降低血压升高有潜在的危害。如果急诊医生选择急性治疗,他们应该考虑老年人副作用增加的风险,并避免比尔斯列出的药物,包括短效硝苯地平和可乐定。
{"title":"Slow on the Draw-ED Management of Elevated BP in Older Adults.","authors":"Kianna Eurick-Bering, Brett Todd, Lauren Cameron-Comasco","doi":"10.1007/s11906-023-01284-y","DOIUrl":"10.1007/s11906-023-01284-y","url":null,"abstract":"<p><strong>Purpose of review: </strong>The purpose of this study is to review data surrounding the emergency department management of elevated blood pressure in older adults, including the management of hypertensive crisis and outpatient management of markedly elevated blood pressure.</p><p><strong>Recent findings: </strong>Acute lowering of blood pressure in older adults with markedly elevated blood pressure may lead to serious complications without improvements in hospital length of stay, return visits, or mortality. Older adults presenting with elevated blood pressures without evidence of end-organ damage should be referred for outpatient management of their blood pressure. Treatment of hypertensive emergency should follow standard guidelines with additional considerations for aging physiology. Acute lowering of elevated blood pressure in older adults without evidence of end-organ damage has the potential for harm. If the emergency physician opts to acutely treat, they should consider the increased risk of side effects in older adults and avoid Beers list medications including short-acting nifedipine and clonidine.</p>","PeriodicalId":10963,"journal":{"name":"Current Hypertension Reports","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138175866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current Hypertension Reports
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1